Publication | Closed Access

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

OncologyCc-486 Versus PembrolizumabClinical TrialsImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentPhase 2MedicineRadiation OncologyLung CancerHealth Sciences